<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Roquefort Therapeutics Plc — News on 6ix</title>
    <link>https://6ix.com/company/roquefort-therapeutics-plc</link>
    <description>Latest news and press releases for Roquefort Therapeutics Plc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 15 Apr 2026 06:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/roquefort-therapeutics-plc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d57be7beedb30cb6f88d7c.webp</url>
      <title>Roquefort Therapeutics Plc</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc</link>
    </image>
    <item>
      <title>Presentation at 18th Annual World Cancer Congress</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/presentation-at-18th-annual-world-cancer-congress</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/presentation-at-18th-annual-world-cancer-congress</guid>
      <pubDate>Wed, 15 Apr 2026 06:00:00 GMT</pubDate>
      <description>Coiled Therapeutics plc announced that its Executive Chairman will present on AO-252, a novel TACC3 inhibitor, at the 18th Annual World Cancer Congress on April 16, 2026. The presentation will highlight AO-252&apos;s potent activity in multiple solid tumors, including brain metastases, and its potential to address significant unmet needs in oncology. This follows recent clinical trial updates demonstrating superior efficacy and durable responses for AO-252 in heavily pre-treated patients, with the co</description>
    </item>
    <item>
      <title>Clinical Trial Update</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/clinical-trial-update-6</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/clinical-trial-update-6</guid>
      <pubDate>Wed, 08 Apr 2026 06:00:00 GMT</pubDate>
      <description>Coiled Therapeutics plc announced positive clinical trial results for its TACC3 inhibitor, AO-252, showing an 80% Clinical Benefit Rate in the Twice-Daily dosing cohort, a significant improvement over the 40% seen with Once-Daily dosing, with durable responses exceeding six months. The drug maintained a benign safety profile with no serious adverse events, and the Maximum Tolerated Dose has not been reached, allowing for continued dose escalation. The company is accelerating its transition to do</description>
    </item>
    <item>
      <title>Total Voting Rights</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/total-voting-rights-908</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/total-voting-rights-908</guid>
      <pubDate>Wed, 01 Apr 2026 06:00:00 GMT</pubDate>
      <description>Coiled Therapeutics plc has announced its total issued share capital, consisting of 425,856,539 ordinary shares of 1p each with voting rights, following its admission to trading on AIM. The company holds no treasury shares, meaning the total number of voting rights is also 425,856,539, which shareholders can use for disclosure calculations under FCA rules.
                Disclaimer*</description>
    </item>
    <item>
      <title>Readmission - Roquefort Therapeutics Plc</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/readmission-roquefort-therapeutics-plc</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/readmission-roquefort-therapeutics-plc</guid>
      <pubDate>Fri, 27 Mar 2026 08:00:00 GMT</pubDate>
      <description>Roquefort Therapeutics PLC&apos;s ordinary shares of 1p each have been cancelled from admission to trading on the London Stock Exchange, effective March 27, 2026, following a transfer to AIM.
                Disclaimer*</description>
    </item>
    <item>
      <title>Investor Presentation</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/investor-presentation-633</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/investor-presentation-633</guid>
      <pubDate>Thu, 26 Mar 2026 13:00:00 GMT</pubDate>
      <description>Roquefort Therapeutics plc announced that following shareholder approval of the acquisition of the exclusive worldwide licence of AO-252 from Coiled Therapeutics, Inc. and the subsequent name change to Coiled Therapeutics plc, effective March 27, 2026, the leadership team will host a live investor presentation on Monday, March 30, 2026, at 2:00 PM BST. The presentation will cover the acquisition and name change, and investors are encouraged to pre-submit questions.
                Disclaimer*</description>
    </item>
    <item>
      <title>Lyramid SPA &amp; MK Cell License Update</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/lyramid-spa-and-mk-cell-license-update</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/lyramid-spa-and-mk-cell-license-update</guid>
      <pubDate>Wed, 25 Mar 2026 07:00:00 GMT</pubDate>
      <description>Roquefort Therapeutics plc has extended the Longstop Dates for both the Lyramid SPA and the MK Cell Out-License agreements with Pleiades Pharma Ltd to December 31, 2026. This extension is necessary to allow Pleiades sufficient time to complete its ongoing fundraising round with GCC investors, as completion of both the Lyramid subsidiary sale and the MK Cell patent out-licensing are contingent on this fundraising. All other terms of the existing agreements remain unchanged.
                Discla</description>
    </item>
    <item>
      <title>Schedule One - Roquefort Therapeutics PLC</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/schedule-one-roquefort-therapeutics-plc</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/schedule-one-roquefort-therapeutics-plc</guid>
      <pubDate>Mon, 02 Mar 2026 08:00:00 GMT</pubDate>
      <description>Roquefort Therapeutics plc will be renamed Coiled Therapeutics plc upon its readmission to AIM on March 27, 2026, following the acquisition of the AO-252 Licence from A2A Pharmaceuticals for approximately £31.90 million, satisfied by the issue of shares. The company is raising £8.5 million at 10 pence per share, anticipating a market capitalization of £42.6 million. The AO-252 molecule, a novel inhibitor targeting TACC3 protein-protein interactions, has shown strong preclinical efficacy in vario</description>
    </item>
    <item>
      <title>Transaction Update &amp; Notice of Intention to Delist</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/transaction-update-and-notice-of-intention-to-delist</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/transaction-update-and-notice-of-intention-to-delist</guid>
      <pubDate>Wed, 25 Feb 2026 07:00:00 GMT</pubDate>
      <description>Roquefort Therapeutics plc is proceeding with a significant transaction involving the acquisition of worldwide exclusive rights to AO-252, a cancer drug candidate targeting TACC3, from Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc. This acquisition is contingent upon the company&apos;s shares being admitted to the AIM market of the London Stock Exchange. Concurrently, Roquefort Therapeutics intends to delist its ordinary shares from the Main Market of the London Stock Exchange, with the deli</description>
    </item>
    <item>
      <title>Research Note Published</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/research-note-published</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/research-note-published</guid>
      <pubDate>Thu, 15 Jan 2026 07:00:00 GMT</pubDate>
      <description>Roquefort Therapeutics plc has announced the publication of a new research note from its broker, SP Angel Corporate Finance LLP, concerning the Company&apos;s proposed transaction with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc. The research note, which can be accessed via a provided link, offers analysis on this ongoing transaction.
                Disclaimer*</description>
    </item>
    <item>
      <title>Clinical Trial &amp; License Agreement Update</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/clinical-trial-and-license-agreement-update</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/clinical-trial-and-license-agreement-update</guid>
      <pubDate>Fri, 12 Dec 2025 07:00:00 GMT</pubDate>
      <description>Roquefort Therapeutics plc has amended its exclusive license agreement for AO-252 with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc., extending the long stop date to March 16, 2026, and increasing the upfront consideration to £31,875,000 in ordinary shares. The Phase I clinical trial for AO-252 has been expanded to include all solid tumours, with prostate cancer now prioritized as the primary indication following positive pre-clinical data and encouraging safety signals, including 100%</description>
    </item>
    <item>
      <title>Conversion of CLNs</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/conversion-of-clns</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/conversion-of-clns</guid>
      <pubDate>Tue, 09 Dec 2025 07:00:00 GMT</pubDate>
      <description>Roquefort Therapeutics plc has announced the conversion of £80,000 in convertible loan notes, resulting in the issuance of 6,282,264 new ordinary shares. The conversion, which includes accrued interest at 12.5% per annum, occurred at prices of 1.81p for £30,000 and 1.29p for £50,000 of the notes. Following this conversion, the company has £257,894 in convertible loan notes outstanding. The new shares are expected to be admitted to trading on the London Stock Exchange around December 16, 2025, br</description>
    </item>
    <item>
      <title>Ex-Entitlement Date - Unlisted RNV Shares</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/ex-entitlement-date-unlisted-rnv-shares</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/ex-entitlement-date-unlisted-rnv-shares</guid>
      <pubDate>Mon, 01 Dec 2025 10:35:00 GMT</pubDate>
      <description>Roquefort Therapeutics plc announced that its ordinary shares will trade ex-entitlement for Unlisted Redeemable Non-Voting Shares starting December 1, 2025. Holders of ordinary shares and convertible loan notes on the register as of November 28, 2025, are eligible to receive these new shares, as are those who purchased ordinary shares on that date. Further details regarding the entitlement ratio and the exact number of shares to be issued will be provided in a subsequent announcement.
          </description>
    </item>
    <item>
      <title>Holding(s) in Company</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/holdings-in-company-1208</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/holdings-in-company-1208</guid>
      <pubDate>Tue, 25 Nov 2025 07:00:00 GMT</pubDate>
      <description>Trevor Reginald has notified Roquefort Therapeutics PLC of a change in his major holding, reducing his voting rights from a previous position of 6.5% to 2.4%, which equates to 3,805,076 shares. This acquisition or disposal of voting rights occurred on November 24, 2025, and the issuer was notified on the same day. The notification indicates that Trevor Reginald is not controlled by any other entity and does not control any other undertakings holding an interest in the issuer.
                Dis</description>
    </item>
    <item>
      <title>Director/PDMR Shareholding</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/directorpdmr-shareholding-1089</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/directorpdmr-shareholding-1089</guid>
      <pubDate>Mon, 24 Nov 2025 07:00:00 GMT</pubDate>
      <description>Roquefort Therapeutics plc announced that Interim Managing Director Dr. Darrin Disley purchased 5,000,000 ordinary shares at an average price of 1.70 pence per share, totaling £85,000. This transaction increases his total shareholding to 7,024,196 ordinary shares, representing 4.46% of the company&apos;s issued capital. The purchase occurred on November 21, 2025, on the London Stock Exchange.
                Disclaimer*</description>
    </item>
    <item>
      <title>Executed License Agreement &amp; Transaction Update</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/executed-license-agreement-and-transaction-update</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/executed-license-agreement-and-transaction-update</guid>
      <pubDate>Tue, 18 Nov 2025 07:00:00 GMT</pubDate>
      <description>Roquefort Therapeutics plc has entered into a binding exclusive license agreement for AO-252, a clinical-stage oncology asset targeting TACC3, with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc. This transaction involves an upfront consideration of £25.5 million satisfied by the issue of ordinary shares, a move to the AIM market, and a placing to raise a minimum of £10.5 million. The company anticipates multiple near-term value inflection points and proposes to change its name to Coiled</description>
    </item>
    <item>
      <title>MK Cell Out-License &amp; Lyramid SPA Update</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/mk-cell-out-license-and-lyramid-spa-update</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/mk-cell-out-license-and-lyramid-spa-update</guid>
      <pubDate>Mon, 03 Nov 2025 07:00:00 GMT</pubDate>
      <description>Roquefort Therapeutics has agreed to out-license its MK Cell patents to Pleiades Pharma Ltd for up to US$25 million in milestone payments, plus a 1.5% royalty on net sales. Milestone payments include US$500,000 upon securing minimum fundraising, potentially increasing to US$650,000, and further payments triggered by regulatory submissions and approvals. Up to US$21 million is tied to achieving various worldwide sales targets. Additionally, the Longstop Date for the Lyramid sale to Pleiades has b</description>
    </item>
    <item>
      <title>Fundraise &amp; Transaction Update</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/fundraise-and-transaction-update</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/fundraise-and-transaction-update</guid>
      <pubDate>Thu, 16 Oct 2025 06:00:00 GMT</pubDate>
      <description>Roquefort Therapeutics has successfully raised £300,000 to fund upfront costs related to a proposed transaction. This funding comprises £200,000 from advance subscription agreements with strategic investors and £100,000 from a loan provided by A2A Pharmaceuticals, Inc., accruing interest at 5%. The loan is repayable upon completion of the proposed transaction, 12 months from the loan date, or six months after termination of the transaction&apos;s term sheet; A2A Pharma has the option to convert the l</description>
    </item>
    <item>
      <title>Interim Results to 30 June 2025</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/interim-results-to-30-june-2025-5</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/interim-results-to-30-june-2025-5</guid>
      <pubDate>Tue, 30 Sep 2025 06:00:00 GMT</pubDate>
      <description>Roquefort Therapeutics announced its interim results for the six months ended June 30, 2025, reporting a net loss of £467,167 and cash at period end of £182,923. The company signed a binding share purchase agreement for the sale of Lyramid Pty Ltd for $10.8 million and a term sheet for the sale of Oncogeni Ltd for up to $12 million. Roquefort raised £236,000 through a private placement for working capital. Post period, the company announced a proposed acquisition of Coiled Therapeutics, Inc. for</description>
    </item>
    <item>
      <title>Investor Presentation via Engage Investor</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/investor-presentation-via-engage-investor-5</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/investor-presentation-via-engage-investor-5</guid>
      <pubDate>Wed, 24 Sep 2025 06:00:00 GMT</pubDate>
      <description>Roquefort Therapeutics PLC will host a live interactive presentation on the Engage Investor platform on September 29, 2025, at 4pm BST. The presentation aims to update investors on the proposed acquisition of Coiled Therapeutics, Inc. and its AO-252 clinical stage program from A2A Pharma. The company encourages current shareholders and interested investors to join the presentation and pre-submit questions via the Engage Investor platform.

                Disclaimer*</description>
    </item>
    <item>
      <title>Proposed Acquisition of Clinical Stage Company</title>
      <link>https://6ix.com/company/roquefort-therapeutics-plc/news/proposed-acquisition-of-clinical-stage-company</link>
      <guid isPermaLink="true">https://6ix.com/company/roquefort-therapeutics-plc/news/proposed-acquisition-of-clinical-stage-company</guid>
      <pubDate>Mon, 08 Sep 2025 06:00:00 GMT</pubDate>
      <description>Roquefort Therapeutics is set to acquire Coiled Therapeutics, Inc. through a reverse takeover for an upfront payment of £30 million in shares. A2A Pharmaceuticals and its investors will provide £6 million in funding over the next two years. The deal includes exclusivity until January 31, 2026, with a US$1 million termination fee. Roquefort intends to carve out Lyramid Pty Ltd and may carve out the MK Cell program for existing shareholders before the transaction completes. Upon completion, the co</description>
    </item>
  </channel>
</rss>